CClinicalTrials.gg
CompletedNCT06424223Updated Jan 3, 2025

Tunnel Access for Horizontal Alveolar Ridge Augmentation

An interventional study of Horizontal Ridge augmentation in Bone Atrophy, Alveolar, Bone Loss and Bone Resorption, sponsored by University of Bari Aldo Moro. Completed at 1 site in Italy. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-03.

Sponsored by University of Bari Aldo Moro · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Minimally invasive procedures with the tunnel technique have been suggested to decrease patient post-operative discomfort and morbidity in oral bone regeneration. In the ridge augmentation tunnel technique, crestal incision and the release of the connective tissue are avoided in order to enhance the blood supply of the flap. This approach preserves the blood circulation and does not damage the periosteum The purpose of this study is to evaluate the clinical outcome of a minimally invasive technique for maxillofacial horizontal bone augmentation .

Read the detailed description

Several techniques have been introduced to minimize the invasiveness involved in oral bone regeneration, to prevent the coronal advancement of the flap, which in turn reduces postoperative discomfort, swelling, complications, and mobility.

The tunnel technique involves making a vertical incision to access the bone defect and inserting the grafts. The significant benefit of this approach is that it may be closed without the need for periosteal incisions. Several tunnel techniques have been described in the literature using various biomaterials including bovine bone, synthetic bone, bovine bone block, allograft block bone, hidroxiapatite. This clinical study assesses the efficiency of a minimally invasive surgical technique for horizontal ridge augmentation using Biphasic Calcium Phosphate and Acellular Dermal Matrix.

This minimally invasive procedure aims to increase the horizontal volume of the edentulous ridge in both its bone component (through the use of Biphasic Calcium Phosphate) and its mucosal component (through the use of Acellular Dermal Matrix). Compared to other traditional techniques, this procedure, performed through a tunnel approach, would significantly reduce the invasiveness of the treatment.

02

Conditions studied

  • Bone Atrophy, Alveolar
  • Bone Loss
  • Bone Resorption
  • Alveolar Bone Loss
  • Alveolar Bone Resorption

Keywords

  • Bone augmentation
  • Bone regeneration
  • Tissues augmentation
  • Ridge augmentation
03

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients had to be healthy according to System of the American Society of Anesthesiology (ASA) and aged 18 years or older

    • No general medical condition representing a contraindication to implant therapy
    • minimum 2 missing teeth in the maxilla or mandible from the canine to the second molar
    • No periodontal disease (periodontal probing depth \<4 mm) or treated periodontitis
    • Good oral hygiene (full mouth plaque index\<25%)
    • Adequate control of inflammation (full mouth bleeding on probing\<25%)

Exclusion criteria

Exclusion Criteria:

  • smoking of more than 15 cigarettes a day • untreated periodontal disease
  • pregnancy or breastfeeding at date of inclusion • acute infections
  • keratinized mucosal tissue less than 2 mm.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Ridge augmentation

    Procedure: Horizontal Ridge augmentation

Interventions

  • ProcedureHorizontal Ridge augmentation

    A vertical full-thickness incision in the mesial aspect of the defect ridge.Microsurgery instruments is subsequently use to carefully elevate the full thickness of the mucosa. Extreme caution must be exercised during these maneuvers to avoid tissue perforation and to maintain the integrity of the periosteum.An dermal matrix is place into the tunnel. A pouch is create between the bone and the matrix and the Biphasic Calcium Phosphate is inserted into the tunnel until the desirable ridge dimensions are obtained. Primary closure of the vertical incisions was achieved with single interrupted sutures.

05

What researchers measure

Primary outcomes

  1. Evaluation of the achievement of an adequate thickness of the alveolar ridge ridge

    Digital intraoral casts will be superimposed to value the gained thickness of the ridge. The assessment of volume increase in the alveolar ridge will be observed within the implant planning software by measuring the variation in the width of the edentulous ridge by matching three scans. The scans will be conducted at baseline (T0), five months after ridge augmentation (T1), and two months after implant insertion (T2). The matching will be performed using corresponding pairs of regions. The thickness of the alveolar ridges on the same cross-section at the level of the implants inserted will be measured in mm using the "distance" tool.

    Time frame: 5 months

Secondary outcomes

  1. Histological analysis of newly formed tissues.

    A histological analysis will be conducted by the pathology laboratory of the Bari University Hospital on a bone biopsy taken at the same time as the implant placement.

    Time frame: 5 months

06

Study locations

1 site
  • Giuseppe D'Albis
    Bari, 70124, Italy
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06424223
Lead sponsor
University of Bari Aldo Moro
Responsible party
Giuseppe D'Albis (Principal Investigator, University of Bari Aldo Moro) — Principal investigator
First posted
May 22, 2024
Start date
Nov 1, 2022
Primary completion
Oct 1, 2024
Completion
Nov 1, 2024
Last update
Jan 3, 2025

Study contacts

Professor Saverio Capodiferro
study director · University of Bari Aldo Moro
Professor Massimo Corsalini
study director · University of Bari Aldo Moro
Dr. D'Albis Giuseppe
principal investigator · University of Bari Aldo Moro

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion